Released May 9, 2016, after the close
10-Q filed May 9, 2016, 39 days after period end · 0001564590-16-018578
Q1 2016 · 10-Q
Revenue$1.32M$1.32M no prior Q1 2015 on file+22.9% vs Q4 2015
Net Income-$8.38M-$8.38M N/M vs Q1 2015N/M vs Q4 2015
EPS Diluted-$0.29-$0.29 N/M vs Q1 2015N/M vs Q4 2015
Operating Income-$7,916,000N/M
Operating Cash Flow-$7,252,000N/M
Free Cash Flowderived-$7,430,000N/M
Margins · derived
Operating margin-598.8%
Net margin-633.7%
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q1 2016 | Q1 2015 | Q1 2014 | Q1 2013 |
|---|---|---|---|---|
| Revenue | $1.32M | — | — | $472.00K |
| Net Income | -$8.38M | -$7.88M | -$6.98M | -$3.55M |
| EPS Diluted | -$0.29 | -$0.38 | -$0.34 | -$2.92 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR